Cancer

Article	Citations
The ever‐increasing importance of cancer as a leading cause of premature death worldwide	1190
Annual report to the nation on the status of cancer, part 1: National cancer statistics	227
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system	177
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma	147
Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities	118
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017	105
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study	97
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach	94
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospectiv	91
Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017	91
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studies	90
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax	88
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis	88
Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years	86
Racial disparities in Black men with prostate cancer: A literature review	85
The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global	81
Impact of the COVID‐19 pandemic on diagnosis of new cancers: A national multicenter study of the Veterans Affairs Healthcare System	74
Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer	69
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial	65
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors	63
Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial	63
Population‐level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures	62
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies	58
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis	56
Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study	55

A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort	55
Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women	53
Loneliness and mental health during the COVID‐19 pandemic in older breast cancer survivors and noncancer controls	53
Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study	52
Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses	50
Health‐related quality of life outcomes among breast cancer survivors	50
What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata	48
Trajectories of fear of cancer recurrence in young breast cancer survivors	47
Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case‐control study	46
The future of cancer screening after COVID‐19 may be at home	46
Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer	45
Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer	45
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibit	44
Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy	44
High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean	44
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies	44
Loneliness and symptom burden in oncology patients during the COVID‐19 pandemic	43
A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia	43
Associations between artificial light at night and risk for thyroid cancer: A large US cohort study	42
What is empathy? Oncology patient perspectives on empathic clinician behaviors	42
Head and neck cancer surgery during the COVID‐19 pandemic: An international, multicenter, observational cohort study	42
A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia	41
Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy	41
Economic distress, financial toxicity, and medical cost‐coping in young adult cancer survivors during the COVID‐19 pandemic: Findings from an online sample	40
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia	40
Symptom clusters in 1330 survivors of 7 cancer types from the PROFILES registry: A network analysis	40
Cell‐free human papillomavirus DNA kinetics after surgery for human papillomavirus–associated oropharyngeal cancer	40
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)	39
JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer	39
Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey	38
Lung cancer statistics, 2023	38
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety	38
A Coala‐T‐Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment	38
Metabolic imaging with hyperpolarized 13C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience	38
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia	37
Strategies to improve diversity, equity, and inclusion in clinical trials	37
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability	36
Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study	36
Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors	36
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients	35
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study	35
Chronic comorbid conditions among adult cancer survivors in the United States: Results from the National Health Interview Survey, 2002‐2018	35
Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer	35
Cancer pain self‐management in the context of a national opioid epidemic: Experiences of patients with advanced cancer using opioids	35
Quality measures for end‐of‐life care for children with cancer: A modified Delphi approach	35
The dual pandemic of COVID‐19 and systemic inequities in US Latino communities	34
Quality of life among survivors of adolescent and young adult cancer in Canada: A Young Adults With Cancer in Their Prime (YACPRIME) study	34
Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria: Validation of DIGEST version 2	34
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01	33
Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group	33

Changes in breast cancer screening rates among 32 community health centers during the COVID‐19 pandemic	33
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies	33
Cause of death during prostate cancer survivorship: A contemporary, US population–based analysis	33
Cancer‐related mortality among people with intellectual disabilities: A nationwide population‐based cohort study	33
Lung cancer screening eligibility and use with low‐dose computed tomography: Results from the 2018 Behavioral Risk Factor Surveillance System cross‐sectional survey	32
Defining disease modification in myelofibrosis in the era of targeted therapy	32
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer	32
Deep learning radiomics of ultrasonography for comprehensively predicting tumor and axillary lymph node status after neoadjuvant chemotherapy in breast cancer patients: A multicenter study	32
Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors	32
Trends in the incidence of early‐onset colorectal cancer in all 50 United States from 2001 through 2017	31
Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy‐naive men: A prospective evaluation of the PLUM cohort	31
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group	31
Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975‐2016	31
Ultrasensitive detection of tumor‐specific mutations in saliva of patients with oral cavity squamous cell carcinoma	31
The mutational landscape of early‐ and typical‐onset oral tongue squamous cell carcinoma	31
Regulatory T cells: Their role in triple‐negative breast cancer progression and metastasis	31
Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cance	31
ChatGPT—A promising generative AI tool and its implications for cancer care	31
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma	30
Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States	30
Young adult cancer caregivers' exposure to cancer misinformation on social media	30
Fear of cancer recurrence and disease progression in long‐term prostate cancer survivors after radical prostatectomy: A longitudinal study	30
Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVID‐19 pandemic among low‐income women in New York City	30
Prevalence of cannabis use among individuals with a history of cancer in the United States	30
Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status	29
A lay navigator‐led, early palliative care intervention for African American and rural family caregivers of individuals with advanced cancer (Project Cornerstone): Results of a pilot randomized trial	29
Cancer‐related inflammation and depressive symptoms: Systematic review and meta‐analysis	29
Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials	28
COVID‐19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system	28
Association of polypharmacy and potential drug‐drug interactions with adverse treatment outcomes in older adults with advanced cancer	28
SARC‐F for screening of sarcopenia among older adults with cancer	27
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920	27
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors	27
Evolving strategies for management of desmoid tumor	27
Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lympho	27
Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial	27
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes	26
Association of area‐level socioeconomic status and non–small cell lung cancer stage by race/ethnicity and health care–level factors: Analysis of the National Cancer Database	26
Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the	26
Cancer‐related impairments and functional limitations among long‐term cancer survivors: Gaps and opportunities for clinical practice	26
Performance of the IBIS/Tyrer‐Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative	26
Psychological distress and associated additional medical expenditures in adolescent and young adult cancer survivors	26
Racial and ethnic disparities in pediatric cancer incidence among children and young adults in the United States by single year of age	26
The efficacy and mechanisms of a guided self‐help intervention based on mindfulness in patients with breast cancer: A randomized controlled trial	26
Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30‐year SIOP‐RTSG experience	26
Cannabis use among cancer survivors in the United States: Analysis of a nationally representative sample	26
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and eff	26
Clinical and organizational risk factors for mortality during deterioration events among pediatric oncology patients in Latin America: A multicenter prospective cohort	25
Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery	25
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia	25
The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort	25
Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data	25
Treatment patterns and survival in patients with early‐onset pancreatic cancer	25
Social needs and health‐related quality of life among African American cancer survivors: Results from the Detroit Research on Cancer Survivors study	25
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma	24
The cumulative incidence of cisplatin‐induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments	24
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings	24
Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab	24
Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single‐arm, prospective phase 2 study	24
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma	24
Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis	24
Blood‐based biomarkers of human papillomavirus–associated cancers: A systematic review and meta‐analysis	24
Comparing adult‐child and spousal caregiver burden and potential contributors	24
Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study	24
Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative	23
Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States	23
Hope and advance care planning in advanced cancer: Is there a relationship?	23
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma	23
Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer	23
Prevalence and risk factors of cancer‐related fatigue in childhood cancer survivors: A DCCSS LATER study	23
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study	23
Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate‐risk and high‐risk head and neck squamous cell carcinoma	23
A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index	23
Interventions to increase racial and ethnic minority accrual into cancer clinical trials: A systematic review	23
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients	23
Association between metabolic syndrome and its components and incident colorectal cancer in a prospective cohort study	23
A novel combined resilience and advance care planning intervention for adolescents and young adults with advanced cancer: A feasibility and acceptability cohort study	22
Patient‐reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis	22
A multi‐institutional phase 2 trial of stereotactic body radiotherapy in the treatment of bone metastases in pediatric and young adult patients with sarcoma	22
AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia	22

Improved survival of patients with myelofibrosis in the last decade: Single‐center experience	22
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia	22
Exemptions to state laws regulating opioid prescribing for patients with cancer‐related pain: A summary	22
Remote triage incorporating symptom‐based risk stratification for suspected head and neck cancer referrals: A prospective population‐based study	22
The cure of leukemia through the optimist's prism	22
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer	22
Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients	22
The Online Cancer Nutrition Misinformation: A framework of behavior change based on exposure to cancer nutrition misinformation	22
Survival outcomes of patients with localized FOXO1 fusion‐positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology	21
Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management	21
Management recommendations for pancreatic manifestations of von Hippel–Lindau disease	21
Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation wit	21
Relationship between insurance status and outcomes for patients with breast cancer in Missouri	21
Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer	21
Systematic review of financial burden assessment in cancer: Evaluation of measures and utility among adolescents and young adults and caregivers	21
Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years	21
Safety of acupuncture in oncology: A systematic review and meta‐analysis of randomized controlled trials	21
Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review‐based cohort study	20
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant pros	20
Disparities in phase 1 cancer clinical trial enrollment	20
Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study	20
A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions	20
Digital stress management in cancer: Testing StressProffen in a 12‐month randomized controlled trial	20
Burden of lymphedema in long‐term breast cancer survivors by race and age	20
Chronic pain severity, impact, and opioid use among patients with cancer: An analysis of biopsychosocial factors using the CHOIR learning health care system	20
De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospecti	20
Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions	20
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes	20
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome	20
Targeted therapy for lung cancer: Beyond EGFR and ALK	20
A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia	20
Optimization of a technology‐supported physical activity promotion intervention for breast cancer survivors: Results from Fit2Thrive	20
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers	20
Multilevel barriers to communication in pediatric oncology: Clinicians' perspectives	19
Presentation, patterns of care, and outcomes of patients with prostate cancer in sub‐Saharan Africa: A population‐based registry study	19
Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer	19
A national quality improvement study identifying and addressing cancer screening deficits due to the COVID‐19 pandemic	19
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas	19
Clinical effects and applications of the gut microbiome in hematologic malignancies	19
Racial disparities in frailty and geriatric assessment impairments in older adults with cancer in the Deep South: Results from the CARE Registry	19
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors	19
Disease characteristics and mortality among Asian women with breast cancer	19
A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma	19
The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas	19
Global, regional, and national cancer deaths and disability‐adjusted life‐years (DALYs) attributable to alcohol consumption in 204 countries and territories, 1990‐2019	19
Consumption of sugar‐sweetened and artificially sweetened beverages and breast cancer survival	19
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis	19
Recent histone deacetylase inhibitors in cancer therapy	19
Vitamin D supplementation increases objective response rate and prolongs progression‐free time in patients with advanced melanoma undergoing anti–PD‐1 therapy	18
Mindfulness‐based stress reduction and cognitive function among breast cancer survivors: A randomized controlled trial	18
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3OAKtrial	18
Impact of the COVID‐19 pandemic on pediatric oncology providers globally: A mixed‐methods study	18
Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial	18
Disparities in cancer genetics care by race/ethnicity among pan‐cancer patients with pathogenic germline variants	18
A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer	18
A network analysis of self‐reported psychoneurological symptoms in patients with head and neck cancer undergoing intensity‐modulated radiotherapy	18
Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma	18
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma	18
Frailty and checkpoint inhibitor toxicity in older patients with melanoma	18
Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study	18
Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240	18
Mind your words: Oncologists' communication that potentially harms patients with advanced cancer: A survey on patient perspectives	18
Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy: A multicentered, randomized controlled trial	18
Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey	18
Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH‐AARP Diet and Health Study cohort	18
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer	18
Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in rel	18
Sensing gastric cancer via point‐of‐care sensor breath analyzer	17
Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer	17
Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad)	17
Validation of the caregiver Pediatric Patient‐Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure	17
	17
Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy	17
The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival	17
Physical fitness and modifiable cardiovascular disease risk factors in survivors of childhood cancer: A report from the SURfit study	17
Intersectionality and cancer survivorship: Sexual orientation and racial/ethnic differences in physical and mental health outcomes among female and male cancer survivors	17
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma	17
Impact of health literacy on shared decision making for prostate‐specific antigen screening in the United States	17
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements	16
A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial	16
Cancer case trends following the onset of the COVID‐19 pandemic: A community‐based observational study with extended follow‐up	16
Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study	16
Effect of an mHealth intervention on physical activity outcomes among young adult cancer survivors: The IMPACT randomized controlled trial	16
Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer	16
Germline mutations and age at onset of lung adenocarcinoma	16
Trends and racial disparities in aggressive end‐of‐life care for a national sample of women with ovarian cancer	16
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies	16
Worldwide trend in human papillomavirus–attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030	16
Differential treatment outcomes in BRCA1/2‐, CDK12‐, and ATM‐mutated metastatic castration‐resistant prostate cancer	16
Substance use, substance use disorders, and treatment in adolescent and young adult cancer survivors—Results from a national survey	16
Primary central nervous system sarcoma with DICER1 mutation—treatment results of a novel molecular entity in pediatric Peruvian patients	16
Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial	16
Individual‐ and neighborhood‐level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California	16
The validity of progression‐free survival 2 as a surrogate trial end point for overall survival	16
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092‐22092 STRASS trial	16